by John R. Fischer
, Senior Reporter | July 25, 2018
OEMs, advocacy groups and nuclear medicine providers worldwide are calling on Congress to provide $20 million toward a domestic supply of Molybdenum-99 (Mo-99) in the U.S.
Addressing their request in a letter, the group called for the Subcommittee on Energy and Water Development to approve a provision in both the House of Representatives and Senate Fiscal Year 2019 Energy and Water Appropriation bills that would help fund production of Mo-99 as part of the National Nuclear Safety Administration’s medical isotope program, stressing the need as necessary to ensuring a “secure supply of Mo-99” is available for the creation and distribution of technetium-99m for use in the diagnosis of cancers and other serious health conditions.
“We are experiencing problems with international sources due to various technical reasons. Mo-99m and Tc-99m are used every day in the clinic, from cancer staging to the detection of cardiac disease to neurological evaluation,” Satoshi Minoshima, the president of the Society of Nuclear Medicine and Molecular Imaging and one of the signatories of the letter, told HCB News. “It is critical for the U.S. to develop sustainable sources of Mo-99m so that we will not be reliant on foreign sources for a product that is essential to healthcare in the U.S.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
More than 50 million scans using Mo-99 are performed annually worldwide, with approximately half taking place in the U.S. The lack of a domestic source, though, has forced the U.S. to rely completely on supplies shipped in from other countries, a complex process that comes with the risk of possible shortages and issues within overseas supply chains.
Under the provision, funding would be provided through the Laboratory and Partnership Support account within the NNSA, aiding in the fulfillment of the objective outlined in the American Medical Isotope Production Act of 2012, which calls for establishment of a sufficient domestic supply of Mo-99.
The parties behind the letter point this out in their argument, along with global supply challenges that place patient access to necessary nuclear medicine procedures at risk and their first-hand accounts of seeing the benefits that Mo-99 brings to patients in more than 30 distinct diagnostic procedures, two of which are myocardial perfusion tests for heart disease and bone scans for determining if a cancer has metastasized.
In addition, the groups ask that the Department of Energy (DOE) be directed to use maximum flexibility to allow pre-award funding for expenses directly related to projects from the beginning of 2018 fiscal year.